A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Completed at 65 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 13th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 5th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 579 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 34th largest by enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2021, is one of 51 in phase 3, and was the 6th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received weekly doses of tirzepatide subcutaneously (SC) for 72 weeks, starting at 2.5 milligrams (mg) for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
Drug: Tirzepatide
Participants received matching placebo SC once weekly (QW).
Other: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Percent Change From Baseline in Body Weight
Percent change from baseline in body weight. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression model using imputed data with baseline body weight, Analysis Country, Sex, Treatment as factors.
Time frame: Week 72
Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program
Percentage of participants who maintain ≥80% of the body weight lost during intensive lifestyle program was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
Time frame: 72 Weeks
Percentage of Participants Who Achieve ≥10%Body Weight Reduction
Percentage of participants who achieve ≥10% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
Time frame: 72 Weeks
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of participants who achieve ≥15% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
Time frame: 72 Weeks
Percentage of Participants Who Achieve ≥20% Body Weight Reduction
Percentage of participants who achieve ≥20% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
Time frame: 72 Weeks
Change From Baseline in Waist Circumference
Change from baseline in waist circumference. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Change From Baseline in Body Weight
Change from baseline in body weight. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Change From Baseline in Body Mass Index (BMI)
Change from baseline in BMI. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Change From Baseline in Systolic Blood Pressure (SBP)
Change from baseline in SBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Change From Baseline in Diastolic Blood Pressure (DBP)
Change from baseline in DBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percent Change From Baseline in Total Cholesterol
Percent change from baseline in total cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol
Percent change from baseline in HDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol
Percent change from baseline in LDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol
Percent change from baseline in VLDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percent Change From Baseline in Triglycerides
Percent change from baseline in triglycerides. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percent Change From Baseline in Free Fatty Acids
Percent change from baseline in free fatty acids. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Change From Baseline in Fasting Glucose
Change from baseline in fasting glucose. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Percent Change From Baseline in Fasting Insulin
Percent change from baseline in fasting insulin. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, 72 Weeks
Change From Baseline in Short Form 36 Version 2 Health Survey Version 2 (SF 36v2) Acute Form Physical Functioning Domain Score
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, 72 Weeks
Change From Baseline in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined using ANCOVA model with Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, 72 Weeks
| Milestone | Placebo | Tirzepatide |
|---|---|---|
| Started | 292 | 287 |
| Received at least one dose of study drug | 292 | 287 |
| Completed | 227 | 252 |
| Not completed | 65 | 35 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lost to follow-up | 24 | 12 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Pregnancy | 2 | 2 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Withdrawal by subject | 28 | 14 |
| Withdrew: Other - as reported by the investigator | 6 | 0 |
Percent change from baseline in body weight. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Body Weight | 3.3 ± 0.60 | -21.1 ± 0.59 |
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression model using imputed data with baseline body weight, Analysis Country, Sex, Treatment as factors.
| percentage of participants | Placebo | Tirzepatide |
|---|---|---|
| Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction | 10.65 | 94.37 |
Percentage of participants who maintain ≥80% of the body weight lost during intensive lifestyle program was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
| percentage of participants | Placebo | Tirzepatide |
|---|---|---|
| Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program | 37.80 | 98.59 |
Percentage of participants who achieve ≥10% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
| percentage of participants | Placebo | Tirzepatide |
|---|---|---|
| Percentage of Participants Who Achieve ≥10%Body Weight Reduction | 4.81 | 88.03 |
Percentage of participants who achieve ≥15% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
| Percentage of participants | Placebo | Tirzepatide |
|---|---|---|
| Percentage of Participants Who Achieve ≥15% Body Weight Reduction | 2.06 | 73.94 |
Percentage of participants who achieve ≥20% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.
| Percentage of participants | Placebo | Tirzepatide |
|---|---|---|
| Percentage of Participants Who Achieve ≥20% Body Weight Reduction | 1.03 | 54.93 |
Change from baseline in waist circumference. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Centimeters (Cms) | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Waist Circumference | 1.1 ± 0.58 | -16.8 ± 0.56 |
Change from baseline in body weight. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).
| kg | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Body Weight | 3.5 ± 0.67 | -21.5 ± 0.65 |
Change from baseline in BMI. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).
| kilogram per meter square (kg/m^2) | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | 1.2 ± 0.23 | -7.7 ± 0.23 |
Change from baseline in SBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| millimeters of mercury (mmHg) | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) | 4.4 ± 0.76 | -5.8 ± 0.73 |
Change from baseline in DBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| mmHg | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) | 2.3 ± 0.53 | -3.4 ± 0.51 |
Percent change from baseline in total cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol | 5.19 ± 1.11 | -3.00 ± 0.97 |
Percent change from baseline in HDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol | 3.6 ± 1.12 | 15.4 ± 1.19 |
Percent change from baseline in LDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol | 6.14 ± 1.71 | -6.07 ± 1.44 |
Percent change from baseline in VLDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol | 3.0 ± 2.32 | -25.6 ± 1.60 |
Percent change from baseline in triglycerides. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Triglycerides | 3.0 ± 2.34 | -25.8 ± 1.61 |
Percent change from baseline in free fatty acids. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Free Fatty Acids | -15.0 ± 2.95 | -33.1 ± 2.20 |
Change from baseline in fasting glucose. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Milligram per deciliter (mg/dL) | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Fasting Glucose | 2.4 ± 0.86 | -8.8 ± 0.82 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percentage of HbA1c | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | 0.01 ± 0.022 | -0.46 ± 0.020 |
Percent change from baseline in fasting insulin. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percent change | Placebo | Tirzepatide |
|---|---|---|
| Percent Change From Baseline in Fasting Insulin | 17.3 ± 4.95 | -39.1 ± 2.46 |
The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.
| T-score | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Short Form 36 Version 2 Health Survey Version 2 (SF 36v2) Acute Form Physical Functioning Domain Score | -0.6 ± 0.39 | 3.3 ± 0.37 |
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined using ANCOVA model with Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.
| score on a scale | Placebo | Tirzepatide |
|---|---|---|
| Change From Baseline in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score | 1.1 ± 1.17 | 13.9 ± 1.10 |
Collected over Baseline up to week 76. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/292 (0.3%) | 14/292 (4.8%) | 172/292 (58.9%) |
| Tirzepatide | 1/287 (0.3%) | 17/287 (5.9%) | 230/287 (80.1%) |
| Event | Placebo | Tirzepatide |
|---|---|---|
| NephrolithiasisRenal and urinary disorders | 3/292 | 0/287 |
| Acute myocardial infarctionCardiac disorders | 0/292 | 1/287 |
| Colitis microscopicGastrointestinal disorders | 0/292 | 1/287 |
| HaematocheziaGastrointestinal disorders | 0/292 | 1/287 |
| PancreatitisGastrointestinal disorders | 0/292 | 1/287 |
| Small intestinal obstructionGastrointestinal disorders | 1/292 | 1/287 |
| Umbilical herniaGastrointestinal disorders | 0/292 | 1/287 |
| Cholecystitis acuteHepatobiliary disorders | 0/292 | 1/287 |
| CellulitisInfections and infestations | 1/292 | 1/287 |
| SepsisInfections and infestations | 1/292 | 1/287 |
| Event | Placebo | Tirzepatide |
|---|---|---|
| NauseaGastrointestinal disorders | 41/292 | 114/287 |
| DiarrhoeaGastrointestinal disorders | 27/292 | 89/287 |
| Covid-19Infections and infestations | 74/292 | 66/287 |
| ConstipationGastrointestinal disorders | 20/292 | 66/287 |
| VomitingGastrointestinal disorders | 4/292 | 52/287 |
| Injection site reactionGeneral disorders | 3/292 | 32/287 |
| Abdominal painGastrointestinal disorders | 7/292 | 30/287 |
| DyspepsiaGastrointestinal disorders | 9/292 | 27/287 |
| Decreased appetiteMetabolism and nutrition disorders | 12/292 | 27/287 |
| HeadacheNervous system disorders | 22/292 | 27/287 |
All randomized participants.
| Age, Continuous(years) | Placebo | Tirzepatide | Total |
|---|---|---|---|
| Mean | 45.70 ± 11.79 | 45.40 ± 12.59 | 45.60 ± 12.18 |
| Sex: Female, Male(Participants) | Placebo | Tirzepatide | Total |
|---|---|---|---|
| Female | 183 | 181 | 364 |
| Male | 109 | 106 | 215 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tirzepatide | Total |
|---|---|---|---|
| Hispanic or Latino | 161 | 151 | 312 |
| Not Hispanic or Latino | 129 | 132 | 261 |
| Unknown or Not Reported | 2 | 4 | 6 |
| Race (NIH/OMB)(Participants) | Placebo | Tirzepatide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 2 | 6 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 32 | 31 | 63 |
| White | 252 | 246 | 498 |
| More than one race | 2 | 6 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Tirzepatide | Total |
|---|---|---|---|
| Argentina | 44 | 43 | 87 |
| Brazil | 60 | 59 | 119 |
| United States | 188 | 185 | 373 |
| Body weight(Kilograms (kg)) | Placebo | Tirzepatide | Total |
|---|---|---|---|
| Mean | 101.29 ± 20.67 | 102.47 ± 22.11 | 101.87 ± 21.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2021 to primary completion in Apr 2023, 24 months.
Results were first posted in May 2024, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide